Effect of furosemide on progression of early onset of acute kidney injury in critically ill children- A randomized double blinded, placebo controlled trial

JIPMER intramural grant0 个研究点目标入组 220 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•All children aged (corrected age) 1 month to 12 years of adult parents with the following criteria with Early onset AKI as defined by p RIFLE classification (Risk stage either urine output or serum creatinine criterion or both) and achieved immediate resuscitation goals (as directed by the treating physician) including fluid resuscitation AND/OR vasoactive therapy to achieve capillary refill of <=2 secs, >5th percentile mean arterial blood pressure (MABP) for age, sex and length or height, normal pulses volume with no differential between peripheral and central pulses. Central venous pressure >=8 cmH2O (if measured), central venous oxygen saturation >=70% (if measured) AND/OR cardiac index between 3.3 and 6.0 L/min/m2 (if measured).

•1. Patient with >= Stage 4 chronic kidney disease (defined by an estimated glomerular filtration rate <30 mL/min/ 1.73 m2), end stage kidney disease on chronic RRT, kidney transplantation or already received RRT in PICU.
•2. Patient with acute pulmonary edema requiring urgent use of furosemide or RRT or patient already receiving continuous furosemide infusion irrespective of dose and duration.
•3. Patient with known or suspected drug allergy to furosemide.
•4. Patient with known or suspected obstructive etiology for AKI.

发起方

JIPMER intramural grant